Related Experiment Videos
Nanotechnology blooms, at last (Review)
Erlinda M Gordon1, Frederick L Hall
1Department of Pediatrics, Children's Hospital of Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 910027, USA. emgordon@epeiusbiotech.com
Oncology Reports
|May 5, 2005
Summary
New nanobiotic medicine, Rexin-G, shows promise for pancreatic cancer. Engineered nanoparticles deliver genes to tumors, with early patients responding favorably to this novel targeted delivery system (TDS).
Area of Science:
- Nanotechnology
- Oncology
- Gene Therapy
Background:
- Pancreatic cancer presents significant treatment challenges due to its aggressive nature and resistance to conventional chemotherapy.
- The human circulatory system poses barriers to effective drug and gene delivery, including turbulence, dilution, filtration, and inactivation.
Purpose of the Study:
- To evaluate the safety and efficacy of engineered nanoparticles utilizing a targeted delivery system (TDS) for treating metastatic pancreatic cancer.
- To translate complex scientific concepts in physiology, biochemistry, and molecular genetics into accessible language regarding nanotechnology and medical delivery.
Main Methods:
- Clinical trials involving intravenous infusions of TDS-encapsulated genetic material (Rexin-G).
- Development of nano-scale gene delivery vehicles engineered for targeted tumor delivery.
- Overcoming physiological barriers within the circulatory system for effective gene delivery.
Main Results:
- Early clinical trials demonstrated favorable responses in all patients receiving Rexin-G.
- The U.S. Food and Drug Administration (FDA) granted orphan drug status to Rexin-G, supporting its development.
- The targeted delivery system effectively delivered therapeutic genes to metastatic tumors.
Conclusions:
- Engineered nanoparticles with a targeted delivery system show potential as a novel treatment for pancreatic cancer.
- Rexin-G represents a promising nanobiotic medicine for refractory metastatic tumors.
- Further development is warranted for this innovative cancer treatment approach.